Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 83

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 83
---
 292 Provision for credit losses1,385 — — 1,385 Interest expense230 2 907 1,139 Pharmaceutical manufacturing, research and development expense— 585 — 585 Depreciation and amortization expense— 214 20 234 General and administrative expense85 722 2,186 2,993 Other income (expense), net292 — — 292 Income tax expense— — 906 906 Net income (loss)8,379 (892)(4,019)3,468 

26

Nine Months Ended September 30, 2025Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$30,077 $2,153 $— $32,230 Other revenue420 116 — 536 Benefit from credit losses(1,635)— — (1,635)Loss on impairment of intangible assets— 209 — 209 Interest expense713 18 2,733 3,464 Pharmaceutical manufacturing, research and development— 1,550 — 1,550 Loss on disposal of inventory— 314 — 314 Depreciation and amortization expense— — 40 40 General and administrative expense236 1,553 7,617 9,406 Other income (expense), net138 1,519 — 1,657 Income tax expense— — 4,220 4,220 Net income (loss)31,321 144 (14,610)16,855 Nine Months Ended September 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$30,519 $1,711 $— $32,230 Other revenue392 3 — 395 Provision for credit losses10,777 — — 10,777 Loss on impairment of intangible assets— 5,771 — 5,771 Interest expense820 7 2,687 3,514 Pharmaceutical manufacturing, research and development expense— 1,635 — 1,635 Depreciation and amortization expense— 1,106 63 1,169 Change in fair value of acquisition-related contingent consideration— (4,